Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
Sponsor
MeMed Diagnostics Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT04389645
Collaborator
(none)
52
1
1.1
45.2
Study Details
Study Description
Brief Summary
The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.
The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
52 participants
Official Title:
Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
Actual Study Start Date
:
Apr 7, 2020
Actual Primary Completion Date
:
May 12, 2020
Actual Study Completion Date
:
May 12, 2020
Outcome Measures
Primary Outcome Measures
- IP-10 levels [up to 24 months]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- PCR- positive for COVID-19
Exclusion Criteria:
- <18 years of age
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rabin Medical Center | Petach Tikva | Israel |
Sponsors and Collaborators
- MeMed Diagnostics Ltd.
Investigators
- Principal Investigator: Shaul Lev, MD, Rabin Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
MeMed Diagnostics Ltd.
ClinicalTrials.gov Identifier:
NCT04389645
Other Study ID Numbers:
- MM-5000-BV
First Posted:
May 15, 2020
Last Update Posted:
May 15, 2020
Last Verified:
May 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: